Loading...

GPCR STRUCTURE THERAPEUTICS INC Expansion Plans 8-K Filing

STRC

GPCR

STRUCTURE THERAPEUTICS INC

(GPCR)

2026 8-K

Positive Trial Results

Corporate Update

License Agreement

Public Offering Announcement

Clinical Results Announced

Corporate Update

Financial Statements

Financial Statements

Financial Results

Q3 Financial Results

Management Changes

Director Appointment

Earnings Reports

Annual General Meeting

Press Release and Conferenc...

Earnings Reports

Earnings Reports

Collaboration Agreement wit...

Private Placement

Earnings Report

Appointment of Director and...

Dismissal of Independent Re...

Earnings Reports

Earnings Reports

Amended and Restated Memora...

External Links:

On March 16, 2026, Structure Therapeutics Inc. announced positive results from its Phase 2 ACCESS II trial for the oral weight-loss drug Aleniglipron, showing up to 16.2% weight loss. This filing indicates significant progress as the company prepares for Phase 3 development, highlighting a strong safety profile across 625 participants.

AI Assistant

STRUCTURE THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.